Jeffrey Wang

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 1 saleMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

—

▼ Sales (2 ops.)

€11k

Latest filing published 25 Apr 2025 for Sonim Technologies INC, €5,732. Read the official filing

Filing timeline

BuySale

Jeffrey Wang

Insider track record

Disclosed buys

Disclosed sells

Signal history

Closed purchases

Market purchases

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Sonim Technologies INC 1 purchase · last 14 Jul 2022

Jeffrey Wang: trading record in brief

All filings by Jeffrey Wang on record concern DNA X, Inc. Between 13 July 2022 and 23 April 2025, the trades on record add up to 8 filings.

On the open market, the record shows 1 purchase and 2 sales worth €11k. The totals do not cover 1 filing with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 5 share grants. 2025 to date brings no purchases and 1 sale.

The record was last updated on 25 April 2025 with an open-market sale (€5,732) in DNA X, Inc. The most recent open-market purchase was published on 14 July 2022, 1,557 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.